Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AX-158 in mild to moderate plaque psoriasis
NCT05725057Phase 2Completed
- Sponsor
- Artax Biopharma
- Start
- Nov 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis comparing AX-158 with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events at 28 days. Started Nov 2023; status: completed.
02
Drugs
AX-158
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05725057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05725057.